Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment
This guidance provides recommendations for the development of antiretroviral drugs regulated within the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus-1 (HIV-1 or HIV) infection.2 Specifically, this guidance addresses the FDA’s current thinking regarding the overall development program and clinical trial designs for antiretroviral drugs to support an indication for the treatment of HIV-1 infection. The organization of the guidance parallels the development plan for a particular drug or biologic.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.